Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**11C-L-deuteriodeprenyl** is a radiolabeled small molecule used as a positron emission tomography (PET) tracer for in vivo imaging of astrocytosis, particularly in neurodegenerative diseases such as Alzheimer's disease and temporal lobe epilepsy. It is a deuterated analog of L-deprenyl (selegiline), labeled with carbon-11. The compound binds selectively and irreversibly to monoamine oxidase B (MAO-B), an enzyme predominantly located in astrocytes within the brain. By acting as a suicide inhibitor, it forms a covalent bond with MAO-B during normal catalytic activity, allowing visualization of reactive astrocytosis—a process associated with neuronal injury and neurodegeneration—via PET imaging. This tracer has been used to study intermediate processes between amyloid deposition and neuronal loss, providing insights into disease mechanisms and potential monitoring of therapeutic interventions[1][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 11C-L-deuteriodeprenyl.